Journal of cancer research and therapeutics最新文献

筛选
英文 中文
Prognostic impact of Fusobacterium nucleatum on survival in colorectal cancer: A systematic review and meta-analysis. 核梭杆菌对结直肠癌患者生存的影响:一项系统综述和荟萃分析。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_38_24
Tianyu Wang, Shengcheng Lin, Yong Ji, Ciren Puqiong, Jidong Gao, Shuluan Li
{"title":"Prognostic impact of Fusobacterium nucleatum on survival in colorectal cancer: A systematic review and meta-analysis.","authors":"Tianyu Wang, Shengcheng Lin, Yong Ji, Ciren Puqiong, Jidong Gao, Shuluan Li","doi":"10.4103/jcrt.jcrt_38_24","DOIUrl":"10.4103/jcrt.jcrt_38_24","url":null,"abstract":"<p><strong>Abstract: </strong>Recent studies have demonstrated a significant correlation between Fusobacterium nucleatum (F. nucleatum) and colorectal cancer. However, the prognostic significance of this microorganism in patients with colorectal cancer remains unclear. This meta-analysis aimed to evaluate the impact of F. nucleatum on the overall survival of patients with colorectal cancer. A thorough literature search of PubMed, Embase, and Cochrane Library databases was conducted until December 2023. The hazard ratio (HR) with the corresponding 95% confidence interval (CI) was analyzed using Review Manager 5.4 software for survival outcomes, including the overall survival (OS). A total of 13 studies, covering 4475 samples with colorectal cancer, were selected based on specified inclusion and exclusion criteria. In the univariate and multivariate analyses, patients with positive or high abundance of Fusobacterium in the cancer tissues displayed poorer OS (univariate HR = 1.28, 95% CI: 1.08-1.53, P = 0.006; multivariate HR = 1.61, 95% CI: 1.37-1.88, P < 0.0001) than those with negative/low bacteria levels. Subgroup analysis revealed that Fusobacterium in cancer tissues was associated with tumor stage and differentiation. Patients with stage III and IV, T3 and T4, or poorly differentiated tumors had a higher abundance of Fusobacterium in cancer tissues than those with stage I and II, T1 and T2, or well-to-moderately differentiated tumors (P < 0.05). No statistically significant difference in lymph node metastasis was observed. These findings suggest that the Fusobacterium microbiome may play a significant role in predicting the survival outcomes in patients with colorectal cancer.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"796-803"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of radical radiotherapy dose on the prognosis of limited-stage thoracic small cell carcinoma of the esophagus: A multicenter retrospective trial from China (CHiSCEC). 放射治疗剂量对有限期胸小细胞癌预后的影响:一项来自中国的多中心回顾性试验(CHiSCEC)。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_425_25
Zhanyuan Li, Qi Zhang, Qifeng Wang, Yaowen Zhang, Yi Wang, Wenbin Shen, Wencheng Zhang, Xiaolin Ge, Xiujun Su, Ning Yang, Lei Li, Jie Ma, Lina Zhao, Bingxu Tan, Wei Dong, Jian Zhang, Daqing Sun, Hongfu Sun, Wei Huang
{"title":"Effect of radical radiotherapy dose on the prognosis of limited-stage thoracic small cell carcinoma of the esophagus: A multicenter retrospective trial from China (CHiSCEC).","authors":"Zhanyuan Li, Qi Zhang, Qifeng Wang, Yaowen Zhang, Yi Wang, Wenbin Shen, Wencheng Zhang, Xiaolin Ge, Xiujun Su, Ning Yang, Lei Li, Jie Ma, Lina Zhao, Bingxu Tan, Wei Dong, Jian Zhang, Daqing Sun, Hongfu Sun, Wei Huang","doi":"10.4103/jcrt.jcrt_425_25","DOIUrl":"10.4103/jcrt.jcrt_425_25","url":null,"abstract":"<p><strong>Background: </strong>The optimal radiation dose for the treatment of small cell carcinoma of the esophagus (SCEC) has not been established. This study aimed to investigate the treatment outcomes and toxicities in patients with limited-stage SCEC (LS-SCEC) treated by radiotherapy.</p><p><strong>Methods: </strong>Patients with LS-SCEC from 14 institutions were retrospectively identified between December 2000 and October 2021. The primary endpoints of the study included overall survival (OS), progression-free survival (PFS), and local regional control (LRC), and the secondary endpoints were treatment-related toxicity parameters. Patients were categorized into a high-dose (HD, ≥ 60 Gy) group and low-dose (LD, <60 Gy) group based on the radiation dose. Additionally, they were classified into two groups based on the treatment sequence: concurrent chemoradiotherapy (CCRT) and sequential chemoradiotherapy (SCRT). A 1:1 propensity score matching (PSM) approach was applied to balance the observable potential confounding factors between the groups.</p><p><strong>Results: </strong>Of the 150 patients included in the study, 56 received LD, and 94 received HD radiotherapy. After 1:1 PSM, the OS, PFS, and LRC in the HD group were higher than those in the LD group; however, the difference was not statistically significant (P > 0.05). No significant differences in survival and the occurrence of treatment-related toxicity were observed between the CCRT and SCRT groups.</p><p><strong>Conclusions: </strong>Neither CCRT nor SCRT was significantly associated with longer survival in LS-SCEC when a higher radiation dose was selected. A lower radiation dose might be a preferable time-dose fraction scheme; however, additional studies are required to validate these findings.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"864-874"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improvement and application of supine position components for lung tumor microwave ablation. 仰卧位组件在肺肿瘤微波消融中的改进与应用。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_108_25
Yanan Zhang, Yue Li, Qiuying Wei, Jun Liu, Huajian Peng, Xiang Gao, Dongsheng Lu, Zhanyu Xu, Nuo Yang
{"title":"Improvement and application of supine position components for lung tumor microwave ablation.","authors":"Yanan Zhang, Yue Li, Qiuying Wei, Jun Liu, Huajian Peng, Xiang Gao, Dongsheng Lu, Zhanyu Xu, Nuo Yang","doi":"10.4103/jcrt.jcrt_108_25","DOIUrl":"10.4103/jcrt.jcrt_108_25","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to evaluate the safety and efficacy of improved supine positioning components for lung tumor microwave ablation (MWA), with the goal of enhancing surgical efficiency, reducing complications, and improving patient experience.</p><p><strong>Materials and methods: </strong>One hundred patients undergoing MWA for lung tumors were randomly divided into two groups (n = 50 each): experimental (using improved components) and control (using traditional components). The improved positioning system included a high-density memory foam head pillow, lumbar and leg pillows, and adjustable fixing bands tailored to individual patient needs. A comparative analysis was performed on the positioning time, surgical localization time, number of intraoperative computed tomography (CT) scans, changes in vital signs, incidence of postoperative complications, and patient satisfaction between the groups.</p><p><strong>Results: </strong>The experimental group showed significantly shorter positioning (9.48 ± 1.79 min) and surgical localization times (15.08 ± 2.76 min) compared to the control group (P < 0.05). They also required fewer intraoperative CT scans and exhibited more efficient surgical procedures. The experimental group demonstrated a smaller fluctuation range in vital signs and a significantly lower incidence of hypoxemia (P < 0.05), indicating enhanced intraoperative safety in the experimental group. Additionally, the experimental group showed lower pneumothorax and hemothorax rates and higher postoperative patient satisfaction scores (P < 0.05).</p><p><strong>Conclusion: </strong>The use of improved positioning components during MWA for lung tumors effectively reduces positioning time, improves surgical efficiency, lowers intraoperative complication risks, and enhances patient satisfaction. Thus, their application may be recommended for lung tumor MWA.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"885-891"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR -mutant advanced non-small cell lung cancer. 微波消融联合第三代表皮生长因子受体酪氨酸激酶抑制剂治疗egfr突变的晚期非小细胞肺癌。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-05-21 DOI: 10.4103/jcrt.jcrt_2418_24
Nana Chen, Xiaojing Tan, Cuiping Han, Feng Zhao, Lu Yang, Dongfeng Wang, Xin Ye, Zhigang Wei
{"title":"Microwave ablation combined with third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment in EGFR -mutant advanced non-small cell lung cancer.","authors":"Nana Chen, Xiaojing Tan, Cuiping Han, Feng Zhao, Lu Yang, Dongfeng Wang, Xin Ye, Zhigang Wei","doi":"10.4103/jcrt.jcrt_2418_24","DOIUrl":"10.4103/jcrt.jcrt_2418_24","url":null,"abstract":"<p><strong>Objectives: </strong>We aimed to verify the efficacy and safety of microwave ablation (MWA) in combination with third-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) administration for EGFR-mutant advanced non-small cell lung cancer (NSCLC).</p><p><strong>Materials and methods: </strong>Individuals with advanced NSCLC and EGFR mutations who underwent third-generation EGFR-TKI treatment and MWA (EGFR-TKI treatment followed by MWA [Group E + M] and MWA followed by EGFR-TKI treatment [Group M + E]) were retrospectively enrolled. The primary endpoint was duration of response (DoR).</p><p><strong>Results: </strong>There were 12 patients in Group E + M and 16 in Group M + E. The overall median DoR was 21.9 months (95% confidence interval [CI]: 17.3-26.4). The median DoR was 25.7 months (95% CI: 20.6-30.9) and 20.5 months (95% CI: 5.9-35.1) in Group E + M and Group M + E ( P = 0.996), respectively. When EGFR-TKIs were used as a first-line treatment, the median DoR overall and that of patients in Groups E + M and M + E were 29.3 months (95% CI: 19.2-39.4), 29.3 months (95% CI: 21.0-37.5), and not reached ( P = 0.252), respectively. Major complications related to pneumothorax were observed in five patients, with no difference observed between the groups.</p><p><strong>Conclusion: </strong>Patients with advanced EGFR-mutant NSCLC who underwent third-generation EGFR-TKI treatment plus MWA had a superior DoR and experienced minimal complications.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":" ","pages":"827-833"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of an evaluation index system for intelligent minimally invasive tumor ablation based on telemedicine. 基于远程医疗的智能微创肿瘤消融评价指标体系的建立。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_727_25
Wuwei Yang, Baorang Zhu, Jing Li, Junxiao Wang, Weijun Fan, Chen Chi, Yumeng Zhang, Fuliang Luo, Zengliang Liu
{"title":"Development of an evaluation index system for intelligent minimally invasive tumor ablation based on telemedicine.","authors":"Wuwei Yang, Baorang Zhu, Jing Li, Junxiao Wang, Weijun Fan, Chen Chi, Yumeng Zhang, Fuliang Luo, Zengliang Liu","doi":"10.4103/jcrt.jcrt_727_25","DOIUrl":"10.4103/jcrt.jcrt_727_25","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to establish an evaluation index system for intelligent minimally invasive tumor ablation based on telemedicine, thereby providing theoretical support for the assessment, application, and promotion of remote intelligent ablation therapies.</p><p><strong>Methods: </strong>An expert consultation questionnaire was developed based on a review of the literature. Purposive sampling was performed to select 16 experts specializing in minimally invasive oncology, telemedicine management, and healthcare informatics. Two rounds of Delphi questionnaire surveys were conducted. The index system was finalized through iterative discussions based on expert feedback. The analytical hierarchy process (AHP) was utilized to determine the indicator weights.</p><p><strong>Results: </strong>Both rounds of the questionnaire achieved 100% response rates. The expert authority coefficient reached 0.789, while the Kendall's W coefficients for the two rounds were 0.138 (P < 0.001) and 0.224 (P < 0.001), respectively. The finalized system comprised 6 first-level indicators, 13 second-level indicators, and 45 third-level indicators, establishing a comprehensive management framework for telemedicine-based intelligent tumor ablation.</p><p><strong>Conclusion: </strong>The evaluation system established in this study demonstrated scientific validity and reliability. It identified critical success factors for implementing remote ablation procedures, offering a practical reference for advancing telemedicine-enabled minimally invasive cancer therapies.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"941-947"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Construction and application of a mortality risk prediction model for patients with lung squamous cell carcinoma: A competing risk analysis. 肺鳞状细胞癌患者死亡风险预测模型的构建与应用:竞争风险分析
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_791_25
Qin Wang, Qianqian Wang, Di Wang, Jiahui Lao, Yang Yang, Fang Tang, Xiaoshuai Zhang
{"title":"Construction and application of a mortality risk prediction model for patients with lung squamous cell carcinoma: A competing risk analysis.","authors":"Qin Wang, Qianqian Wang, Di Wang, Jiahui Lao, Yang Yang, Fang Tang, Xiaoshuai Zhang","doi":"10.4103/jcrt.jcrt_791_25","DOIUrl":"10.4103/jcrt.jcrt_791_25","url":null,"abstract":"<p><strong>Background: </strong>Lung squamous cell carcinoma (LUSC) is the dominant histological subtype of lung cancer, accounting for 30% of all cases. Most patients develop distant metastases by the time they are diagnosed with the disease, owing to a delay in the appearance of symptoms. Therefore, accurate prognostic prediction is essential for personalized treatment. However, existing models tend to ignore competing risks, leading to an overestimation of the incidence. This study aimed to construct an accurate mortality risk prediction model for LUSC patients from the perspective of competing risks.</p><p><strong>Methods: </strong>A total of 28,312 patients with LUSC from 2000 to 2019 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Potential predictors included age, sex, treatments, race, marital status, tumor site, differentiation, and stage. Statistical analyses were performed using cause-specific hazard and Fine-Gray risk models to assess competing risks. Model performance was evaluated using Harrell's concordance index and calibration plots.</p><p><strong>Results: </strong>Age, sex, treatment, marital status, tumor site, differentiation, and stage significantly affected the prognosis of LUSC. Both risk models showed good predictive power. The Fine-Gray risk model was slightly better than the cause-specific hazard model in terms of the 3- and 5-year mortality. The key risk factors for LUSC outcomes included age, male gender, absence of surgery, chemotherapy or radiotherapy, being unmarried or divorced, primary tumors in the lower lobe or main bronchus, low differentiation, and high tumor stage.</p><p><strong>Conclusion: </strong>The Fine-Gray model excels in predicting LUSC death risk and holds significant clinical value.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"810-817"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of postoperative adjuvant therapy for early-stage cervical cancer: A surveillance, epidemiology, and end results analysis. 早期宫颈癌术后辅助治疗的比较:监测、流行病学和最终结果分析。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_2085_24
Le Zhou, Yu Bai, Peng Diao, Shuai Zeng, Chuntang Sun
{"title":"Comparison of postoperative adjuvant therapy for early-stage cervical cancer: A surveillance, epidemiology, and end results analysis.","authors":"Le Zhou, Yu Bai, Peng Diao, Shuai Zeng, Chuntang Sun","doi":"10.4103/jcrt.jcrt_2085_24","DOIUrl":"10.4103/jcrt.jcrt_2085_24","url":null,"abstract":"<p><strong>Objectives: </strong>To compare the effects of different adjuvant treatments for different pathological types of early-stage cervical cancer post-surgery.</p><p><strong>Materials and methods: </strong>Patients with International Federation of Gynecology and Obstetrics (FIGO) stages I-II squamous cell carcinoma (SCC), adenocarcinoma (ADC), and adenosquamous carcinoma (ASC) who underwent hysterectomy and postoperative radiotherapy (RT) from 2004 to 2015 in the surveillance, epidemiology, and end results program database were analyzed. The clinicopathological characteristics and survival rates were compared.</p><p><strong>Results: </strong>A total of 5444 cases were included. ADC had the highest 5-year overall survival (OS) and cervical carcinoma-specific survival (CCSS) rates, followed by SCC and ASC. No significant difference in prognosis was noted among the three histological subtypes when treated with chemoradiation therapy (CRT). However, the survival benefit for ASC was significantly lower than that for SCC (hazard ratio [HR], 1.625; 95% confidence interval [CI], 1.024-2.579; P = 0.039) when treated with RT alone. The prognosis of FIGO stage I patients was significantly better with RT than with CRT (HR, 0.766; 95% CI, 0.622-0.943; P = 0.012). No significant differences in CCSS were observed between patients (stages I and II) treated with external beam RT (EBRT) and EBRT + intracavity brachytherapy.</p><p><strong>Conclusion: </strong>No significant differences in OS and CCSS were observed among the three histological subtypes. The prognosis of ASC patients who received CRT was better than that of those who received RT alone. Patients with stage I tumors could obtain better survival with RT alone. The addition of brachytherapy to EBRT yielded no benefits across the three histological subtypes.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"834-841"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing long-term survival prognosis with surgery-based systemic treatment of gastrointestinal stromal tumors: A population-based study. 一项基于人群的研究:比较胃肠道间质瘤手术系统性治疗的长期生存预后。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_2100_24
Fuli Gao, Xiaodan Xu
{"title":"Comparing long-term survival prognosis with surgery-based systemic treatment of gastrointestinal stromal tumors: A population-based study.","authors":"Fuli Gao, Xiaodan Xu","doi":"10.4103/jcrt.jcrt_2100_24","DOIUrl":"10.4103/jcrt.jcrt_2100_24","url":null,"abstract":"<p><strong>Background: </strong>To date, the optimal sequence of systemic therapy (ST) and surgical resection for gastrointestinal stromal tumors (GISTs) remains unknown. This study aimed to compare the long-term outcomes of different ST approaches when combined with surgery.</p><p><strong>Subject and methods: </strong>Data on GISTs were retrospectively collected from the Surveillance, Epidemiology, and End Results database. The patients were divided into three groups: preoperative ST, postoperative ST, and their combination. The Cox proportional-hazards model was used to analyze risk factors for overall survival (OS) and cancer-specific survival (CSS). Furthermore, the Kaplan-Meier method was employed to compare survival differences in OS and CSS. To minimize the confounding factors, a 1:1:1 propensity score matching method was used. The results of the subgroup analyses were displayed using forest plots.</p><p><strong>Results: </strong>Among the 3774 patients, 518 (13.7%) received preoperative ST, 2799 (74.2%) received postoperative ST, and 457 (12.1%) received combined therapy. The median survival times were 42, 60, and 41 months for the preoperative ST, postoperative ST, and combined therapy groups, respectively. Kaplan-Meier curves showed no significant differences in OS and CSS among the groups before and after matching. Cox regression analysis, with adjustment for variables, revealed no survival advantage among the groups. Subgroup analyses showed that male patients, patients with localized disease, and patients with a tumor size <75 mm could achieve an OS benefit from postoperative ST (P < 0.05).</p><p><strong>Conclusion: </strong>Surgery-based systemic therapies provide a comparable long-term survival prognosis for patients with GISTs. In addition, some patients may achieve an OS benefit from postoperative ST.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"842-850"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994848","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Primary adrenal NK/T lymphoma: A case report of a rare tumor. 原发性肾上腺NK/T淋巴瘤:一例罕见肿瘤。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_730_24
Jinzhao Men, Jianyi Li, Demin Fan, Jin Wang
{"title":"Primary adrenal NK/T lymphoma: A case report of a rare tumor.","authors":"Jinzhao Men, Jianyi Li, Demin Fan, Jin Wang","doi":"10.4103/jcrt.jcrt_730_24","DOIUrl":"10.4103/jcrt.jcrt_730_24","url":null,"abstract":"<p><strong>Abstract: </strong>Natural killer/T-cell lymphoma (NKTCL) is a subtype of non-Hodgkin's lymphoma characterized by rapid progression. It infrequently involves the adrenal glands and exhibits swift advancement. A 52-year-old woman was admitted to the hospital with bilateral renal pain. The patient was diagnosed with adrenal NKTCL by puncture biopsy and subsequently underwent a modified SMILE chemotherapy regimen at our institution. During the initial stages of chemotherapy, the patient experienced myelosuppression, which resulted in a severe infection, shock, and eventual death. The SMILE regimen is associated with adverse effects and carries the risk of fatality due to complications related to chemotherapy. Therefore, there is an immediate need for novel chemotherapy regimens that demonstrate efficacy while minimizing adverse effects.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"960-962"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer. 新辅助化疗免疫治疗局部晚期可切除食管癌的疗效观察。
IF 1.3
Journal of cancer research and therapeutics Pub Date : 2025-09-01 Epub Date: 2025-09-04 DOI: 10.4103/jcrt.jcrt_583_25
Yan Yi, Qiang Cao, Hongmei Zhang, Bin Zhang, Ruidan Zhang, Xinwei Li, Lingshuo Kong, Baosheng Li
{"title":"Efficacy of neoadjuvant chemoimmunotherapy in locally advanced resectable esophageal cancer.","authors":"Yan Yi, Qiang Cao, Hongmei Zhang, Bin Zhang, Ruidan Zhang, Xinwei Li, Lingshuo Kong, Baosheng Li","doi":"10.4103/jcrt.jcrt_583_25","DOIUrl":"10.4103/jcrt.jcrt_583_25","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the efficacy and safety of neoadjuvant chemoimmunotherapy (NICT) in treating locally advanced resectable esophageal squamous cell carcinoma (ESCC).</p><p><strong>Materials and methods: </strong>This retrospective analysis included 379 patients, who received NICT (PD-1 inhibitors + chemotherapy) before surgery at Shandong Cancer Hospital from January 1, 2020, to January 1, 2025. Pathological responses were assessed using standardized criteria, including pathological complete response (pCR), major pathological response (MPR), and tumor regression grade (TRG). Survival analysis was performed using Kaplan-Meier methods, and multivariate Cox regression models were constructed to evaluate the relationship between NICT and survival outcomes.</p><p><strong>Results: </strong>The pCR, MPR, and significant tumor reduction rates were 27.2%, 41.8%, and 81.6%, respectively. Poor tumor differentiation and early clinical stage were associated with improved treatment responses. Patients achieving pCR, MPR, or TRG0-1 had significantly better overall survival rates compared with other groups (P < 0.0001). NICT demonstrated acceptable toxicity, with anastomotic leakage (9.0%) and pneumonia (17.9%) being the primary complications.</p><p><strong>Conclusion: </strong>NICT significantly improves pathological response and survival rates in patients with locally advanced resectable ESCC, with a favorable safety profile. These findings highlight the potential of NICT to transform the treatment landscape of ESCC. Future research should focus on the optimizing treatment regimens, identifying predictive biomarkers, and reducing toxicity to improve clinical outcomes and achieve personalized treatment.</p>","PeriodicalId":94070,"journal":{"name":"Journal of cancer research and therapeutics","volume":"21 4","pages":"934-940"},"PeriodicalIF":1.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144994795","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信